AAAAAA
Results:
1-13
|
Results: 13
Authors:
Soignet, SL
Frankel, SR
Douer, D
Tallman, MS
Kantarjian, H
Calleja, E
Stone, RM
Kalaycio, M
Scheinberg, DA
Steinherz, P
Sievers, EL
Coutre, S
Dahlberg, S
Ellison, R
Warrell, RP
Citation: Sl. Soignet et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J CL ONCOL, 19(18), 2001, pp. 3852-3860
Authors:
He, LZ
Tolentino, T
Grayson, P
Zhong, S
Warrell, RP
Rifkind, RA
Marks, PA
Richon, VM
Pandolfi, PP
Citation: Lz. He et al., Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia, J CLIN INV, 108(9), 2001, pp. 1321-1330
Authors:
Jurcic, JG
Nimer, SD
Scheinberg, DA
DeBlasio, T
Warrell, RP
Miller, WH
Citation: Jg. Jurcic et al., Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia, BLOOD, 98(9), 2001, pp. 2651-2656
Authors:
Soignet, SL
Miller, VA
Pfister, DG
Bienvenu, BJ
Ho, R
Parker, BA
Amyotte, SA
Cato, A
Warrell, RP
Citation: Sl. Soignet et al., Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550), CLIN CANC R, 6(5), 2000, pp. 1731-1735
Authors:
Camacho, LH
Soignet, SL
Chanel, S
Ho, R
Heller, G
Scheinberg, DA
Ellison, R
Warrell, RP
Citation: Lh. Camacho et al., Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide, J CL ONCOL, 18(13), 2000, pp. 2620-2625
Authors:
Brooks, AD
Tong, W
Benedetti, F
Kaneda, Y
Miller, V
Warrell, RP
Citation: Ad. Brooks et al., Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery, CANC CHEMOT, 46(4), 2000, pp. 313-318
Authors:
Novick, SC
Warrell, RP
Citation: Sc. Novick et Rp. Warrell, Arsenicals in hematologic cancers, SEMIN ONCOL, 27(5), 2000, pp. 495-501
Authors:
Rego, EM
He, LZ
Warrell, RP
Wang, ZG
Pandolfi, PP
Citation: Em. Rego et al., Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR alpha and PLZF-RAR alpha oncoproteins, P NAS US, 97(18), 2000, pp. 10173-10178
Authors:
Roboz, GJ
Dias, S
Lam, G
Lane, WJ
Soignet, SL
Warrell, RP
Rafii, S
Citation: Gj. Roboz et al., Arsenic trioxide induces dose- and time-dependent apoptosis of endotheliumand may exert an antileukemic effect via inhibition of angiogenesis, BLOOD, 96(4), 2000, pp. 1525-1530
Authors:
Warrell, RP
Citation: Rp. Warrell, Gallium nitrate and bone metastases, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 483-492
Authors:
Warrell, RP
Citation: Rp. Warrell, Re: Therapeutic targeting of transcription in acute promyelocytic leukemiaby use of an inhibitor of histone deacetylase - Reply, J NAT CANC, 91(5), 1999, pp. 476-476
Authors:
Soignet, SL
Tong, WP
Hirschfeld, S
Warrell, RP
Citation: Sl. Soignet et al., Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia, CANC CHEMOT, 44(5), 1999, pp. 417-421
Authors:
Warrell, RP
Pandolfi, PP
Citation: Rp. Warrell et Pp. Pandolfi, Treatment of acute promyelocytic leukemia with arsenic trioxide - Reply, N ENG J MED, 340(13), 1999, pp. 1044-1045
Risultati:
1-13
|